SenesTech, Inc. (SNES) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. SenesTech, Inc. is a smaller reporting company developing and commercializing fertility control products for pest management, primarily targeting rat and mouse populations. The company's product portfolio includes ContraPest (liquid bait) and the Evolve line (soft bait containing cottonseed oil), which launched in 2024 and now represents the majority of revenue. The company is headquartered in Surprise, Arizona.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue (Net) | $493,000 | $485,000 |
| Gross Profit | $338,000 | $313,000 |
| Gross Margin | 68.6% | 64.5% |
| Operating Loss | $(2,119,000) | $(1,663,000) |
| Net Loss | $(2,063,000) | $(1,665,000) |
| Cash & Equivalents (End of Period) | $6,804,000 | $1,655,000 |
| Short-term Investments | $0 | $994,000 |
| Total Debt (Notes Payable) | $191,000 | N/A |
| Operating Cash Flow | $(1,929,000) | $(1,557,000) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 2% year-over-year to $493,000. This was driven by an 8.9% increase in Evolve product sales (now 85% of total revenue), partially offset by a decline in ContraPest sales.
- Margin Expansion: Gross margin improved to 68.6% from 64.5% due to production efficiencies and favorable product mix.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 31% to $2.04 million. This increase was primarily due to $213,000 in legal fees related to a litigation settlement and $230,000 in severance costs.
- Liquidity Position: Cash and cash equivalents decreased by $771,000 during the quarter to $6.8 million, despite a $1.0 million maturity of short-term investments. The company utilized $173,000 in net proceeds from an At-The-Market (ATM) equity offering.
Outlook, Risks, and Management Commentary
- Liquidity Runway: Management expects current cash resources, combined with anticipated revenue, to fund operations into the third quarter of 2027. This projection assumes no significant changes in working capital and does not include additional capital raises.
- Capital Needs: The company has an accumulated deficit of $144.5 million. While the ATM facility has approximately $7.3 million in remaining capacity, additional financing may be required if revenue growth targets are not met or expenses exceed expectations.
- Legal Resolution: A significant legal action filed by Liphatech Inc. in December 2024 regarding trade secrets and breach of contract was settled in March 2026. All claims were dismissed.
- Leadership Change: Effective May 6, 2026, Michael Edell was appointed President and CEO, succeeding Joel Fruendt. Mr. Fruendt is receiving severance benefits including salary continuation through December 2026 and accelerated stock option vesting.
- Risks: Key risks include the need for continued equity financing, market acceptance of fertility control products, regulatory changes regarding rodenticides, and the ability to scale manufacturing.
Investor Verification Checklist
- Cash Runway Validity: Verify the assumptions behind the "third quarter 2027" liquidity projection, specifically regarding the rate of revenue growth versus the burn rate of ~$2 million per quarter.
- Product Mix Sustainability: Confirm the continued dominance of the Evolve product line (85% of revenue) and the trajectory of the declining ContraPest line.
- One-Time Expenses: Assess the impact of the $213,000 legal settlement and $230,000 severance on future SG&A trends to determine normalized operating costs.
- ATM Capacity: Monitor the utilization of the remaining $7.3 million ATM facility and the potential for dilution if further equity raises are needed before profitability is achieved.
- Customer Concentration: Review the concentration risk where Customer A represented 17% and Customer B represented 10% of Q1 2026 revenue.